The Covid-19 vaccine developed by Oxford university and AstraZeneca has shown greater than expected efficacy.
When the vaccine was given as a half dose, followed by a full one at least one month later, efficacy was 90 per cent. When the jab was given as two full doses at least one month apart, efficacy was 62 per cent. The average efficacy was 70 per cent.
All results were statistically significant and greater than the efficacy sought by both the US Food and Drug Administration and the European Medicines Agency.
AstraZeneca said it would submit the data for regulatory approval “immediately”.